Mathiesen ER, Ali N, Alibegovic AC, et al. - Treatment with insulin detemir (detemir) vs other basal insulins in women with preexisting diabetes was correlated with a similar risk of major congenital malformations, perinatal or neonatal death, hypoglycemia, preeclampsia, and stillbirth.

• Included were 1,457 women; 727 received detemir and 730 received other basal insulins.

• One or more congenital malformations (major plus minor) showed crude prevalence of 9.4% vs 12.6%, with a similar risk difference before and after adjustment for confounders.

• With detemir vs other basal insulins, lower maternal HbA1c during the first trimester (6.5% vs 6.7%) and the second trimester (6.1% vs 6.3%) and a lower prevalence of major hypoglycemia (6.0% vs 9.0%), preeclampsia (6.4% vs 10.0%), and stillbirth (0.4% vs 1.8%) were evident.

• No significant differences were evident postadjustment.